Bergen, Norway, 1 Nov 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces that data and analysis from its Phase Ib/II clinical trial with BGB324 in patients with acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), has been selected for presentation at the 59th … Read more
Bergen, Norge, 24 oktober 2017 – BerGenBio ASA (OSE: BGBIO) ( http://www.bergenbio.com ), er et bioteknologiselskap i klinisk fase som utvikler nye, selektive Axl kinase hemmere til bruk i flere kreftindikasjoner. Selskapet kunngjør at den første pasienten har blitt dosert i fase 2 studiet, som evaluerer selskapets mest avanserte legemiddelkandidat mot kreft, BGB324, i kombinasjon med KEYTRUDA® (pembrolizumab) … Read more
Bergen, Norway, 24 Oct 2017 – BerGenBio ASA (OSE: BGBIO) ( http://www.bergenbio.com ), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class Axl kinase inhibitors to treat multiple cancer indications, announces that the first patient has been dosed in a Phase II trial evaluating the Company’s lead product BGB324 in combination with KEYTRUDA® (pembrolizumab) in patients … Read more
Bergen, Norway, 19 October 2017 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class Axl kinase inhibitors to treat multiple cancer indications, announces that the first patient has been dosed in a Phase II trial evaluating the Company’s lead product BGB324 in combination with KEYTRUDA® (pembrolizumab) in patients … Read more
Bergen, Norge, 19 oktober 2017 – BerGenBio ASA (OSE: BGBIO), er et bioteknologiselskap i klinisk fase som utvikler nye, selektive Axl kinase hemmere til bruk i flere kreftindikasjoner. Selskapet kunngjør at den første pasienten har blitt dosert i fase 2 studiet, som evaluerer selskapets mest avanserte legemiddelkandidat mot kreft, BGB324, i kombinasjon med KEYTRUDA® (pembrolizumab) … Read more
Bergen, Norway, October 18, 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces that the randomised Phase 1b/2 clinical study of BGB324 in combination with either the MAPK inhibitors MEKINIST® (trametinib) plus TAFINLAR® (dabrafenib) or the immune checkpoint inhibitor KEYTRUDA® (pembrolizumab) in patients with … Read more
Bergen, Norge, 18. oktober 2017 – BerGenBio ASA (OSE: BGBIO), et bioteknologiselskap i klinisk fase som utvikler nye, selektive Axl kinase hemmere til bruk i flere kreftindikasjoner, kunngjør at en randomisert fase 1b/2 klinisk studie av BGB324 i kombinasjon med enten MAPK-hemmeren MEKINIST® (trametinib) og TAFINLAR® (dabrafenib) eller `immun checkpoint’ hemmeren KEYTRUDA® (pembrolizumab) har god … Read more
Bergen, Norway, October 16, 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces presentations on three ongoing Phase 2 clinical trials with BGB324 in lung cancer patients at the 18th World Conference on Lung Cancer in Yokohama, Japan. BGB324, a first-in-class selective Axl inhibitor, … Read more
Bergen, Norge, oktober 16, 2017 – BerGenBio ASA (OSE:BGBIO), et onkologisk bioteknologiselskap i klinisk fase som utvikler “first-in-class” legemidler mot nye medikamentmål (drug targets) som driver aggressiv kreft, presenterer tre av selskapets pågående fase 2 kliniske studier med BGB324 i pasienter med lungekreft på den 18ende verdenskonferansen om lungekreft i Yokohama, Japan. BGB324, en “first-in-class” … Read more
Bergen, Norway, Oct 12 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces that the clinical trial of BGB324 in combination with either MEKINIST® (trametinib) plus TAFINLAR® (dabrafenib) or KEYTRUDA® in advanced melanoma, will be presented at the 9th World Congress of Melanoma in … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.